About this trial

The objective of the study is to evaluate an ultraportable ultrasound device, Hepatoscope, for the non-invasive assessment of hepatic steatosis in patients with metabolic-dysfunction associated liver diseases (MASLD), by comparing its measurements with current diagnostic modalities, such as MRI-PDFF.

Eligibility criteria

Qualifiers

Adult patient below 80 yo

Patients with MASLD/MASH recruited in interventional trials requiring MRI PDFF +/- MRE per interventional protocol, OR

Patients with MASLD/MASH recruited in prospective cohorts requiring MRI PDFF +/- MRE per interventional protocol, OR

Patients referred to MRI-PDFF or MRE.

Disqualifiers

Patient in their minority (less than 18 yo) or older than 80 yo,

Patient with active implants,

Patient presenting with a wound where the Hepatoscope exam shall be performed (abdominal right upper quadrant)

Patient with a history of decompensated cirrhosis,

Trial design

Treatments tested in this trial

  • Liver ultrasound

Treatment groups

120 Participants
are divided into 1 treatment group

Locations

3
University Hospital Angers49933, Angers France
Beaujon University Hospital92110, Clichy France
Pitie Salpetriere University Hospital75013, Paris France

Sponsors and collaborators

E-Scopics

Lead sponsor